A Scoping Review of Emerging Treatments in the Pipeline for Idiopathic Pulmonary Fibrosis: Future Perspectives
Open Access
- 5 June 2026
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 14 (6) , 1293
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is an incurable disease with limited therapeutic options and a poor prognosis. Current standard therapies are characterized by drugs or surgical strategies with limited effects, as they are either not curative or their use is restricted to a specific subset of the population. The aim of this scoping review is to evaluate the drugs currently under investigation in Phase II and Phase III trials and provide an overview of the mechanisms of new therapeutic strategies for IPF. Methods: The search strategy was conducted in accordance with PRISMA guidelines and included studies conducted on adults with IPF retrieved from the registered ClinicalTrials.gov database up to 31 December 2025. Results: Nineteen studies were included. The clinical trials investigate key signaling pathways and molecular targets, including MAPK, RhoA/ROCK, PDE4B/cAMP, Wnt/β-catenin, Hedgehog/SMO, IL-11/STAT3, and LPA/autotaxin, as well as extracellular receptors and mediators such as CSF1R, TBXA2R, and WISP1. Conclusions: Ongoing clinical research in IPF reflects a broad diversification of molecular targets; however, translational success remains limited. Current evidence suggests that biological complexity, pathway redundancy, and systemic constraints significantly restrict the clinical impact of single-target strategies. Future progress will likely depend on improved patient stratification, combination approaches, and biomarker-guided trial design rather than isolated pathway modulation.Keywords
Funding Information
- Italian Ministry of Health, Rome, Italy
This publication has 75 references indexed in Scilit:
- Unmet needs and emerging pharmacotherapies for autoimmune connective tissue disease-associated interstitial lung diseasesAutoimmunity Reviews, 2025
- HMGB1 mediates epithelial-mesenchymal transition and fibrosis in silicosis via RAGE/β-catenin signalingChemico-Biological Interactions, 2025
- Pulmonary Hypertension in Interstitial Lung DiseaseChest, 2024
- Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and IndicationsDrugs in R&D, 2024
- Catch your breath: The protective role of the angiotensin AT2 receptor for the treatment of idiopathic pulmonary fibrosisBiochemical Pharmacology, 2023
- Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary FibrosisJAMA, 2023
- Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary FibrosisChest, 2018
- A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung TransplantationThe Journal of Heart and Lung Transplantation, 2015
- Sustained β‐catenin activity in dermal fibroblasts promotes fibrosis by up‐regulating expression of extracellular matrix protein‐coding genesThe Journal of Pathology, 2014
- The Hedgehog System Machinery Controls Transforming Growth Factor-β–Dependent Myofibroblastic Differentiation in HumansThe American Journal of Pathology, 2012